A Multi-Level Strategy for De-implementing Mammography Overuse Among Older Women
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorColumbia University
About this trial
This project aims to advance methodological and theoretical approaches for developing, selecting, refining, and piloting a multilevel de-implementation strategy to reduce the overuse of screening mammography in women aged ≥75 years. Informed by an innovative participatory, stakeholder-driven innovation tournament and a discrete choice experiment, the research team identified, prioritized, and tailored a multilevel de-implementation strategy. The research team will conduct a cluster randomized controlled trial (at the provider level) to test the impact of the provider- and patient-level components of the multilevel strategy on screening mammography use, and secondarily, on provider referrals/orders for screening mammography. The organizational level components of the multilevel strategy will be implemented among all participants, not via random assignment.
Eligibility criteria
Qualifiers
English- or Spanish-speaking women based on preferred language in electronic health record
Aged 75 and older at the time of their scheduled primary care visit
Women who have a primary care visit scheduled within the next 2-4 weeks
Women who have not had a screening mammogram 6 months prior to their scheduled primary care visit but have had a screening mammogram 7-18 months prior to their scheduled primary care visit
Disqualifiers
Women with a history of atypical ductal hyperplasia (ADH) or non-invasive or invasive breast cancer (assessed via ICD 10 code)
Women with dementia (assessed via ICD 10 code)
ICD codes to use across exclusion criteria: F01-F03, Z85.3, G30-G31, N60, C50, or D05
Specialists
Trial design
Treatments tested in this trial
- Enhanced Usual Care
- Multilevel De-Implementation Strategy
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Columbia University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov